Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukemias

Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate

Abstract

Engagement of NKG2D by their ligands (NKG2D-L), as the human major histocompatibility complex class I-related molecules MIC-A and the UL16-binding proteins, on cytolytic lymphocytes leads to the enhancement of antitumour effector functions. These ligands are missing or expressed at very low levels on leukaemic cells; furthermore, they can be shed by tumour cells and inhibit cytolytic activity of lymphocytes. Herein, we show that in vivo administration of all-trans-retinoic acid (ATRA) or the histone deacetylase inhibitor sodium valproate (VPA) to patients affected with acute myeloid leukaemia (AML) M3 or M1 respectively, leads to the induction of transcription and expression of NKG2D-L at the surface of leukaemic cells. Apparently, no detectable shedding of the soluble form of these molecules was found in patients' sera. Conversely, AML blasts from patients treated with chemotherapy not including ATRA or VPA did not show any induction of NKG2D-L transcription. Furthermore, upon therapy with ATRA or VPA, leukaemic blasts become able to trigger lytic granule exocytosis by autologous CD8+ T and natural killer lymphocytes, as shown by CD107a mobilization assay, followed by leukaemic cell lysis. These findings indicate that ATRA and VPA may contribute to the activation of cytolytic effector lymphocytes in vivo, possibly enhancing their anti-leukaemic effect.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T . Broad tumour- associated expression and recognition by tumour-derived γδ T cells of MIC-A and MIC-B. Proc Natl Acad Sci USA 1999; 96: 6879–6884.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Groh V, Steinle A, Bauer S, Spies T . Recognition of stress-induced MHC molecules by γδ T cells. Science 1998; 279: 1737–1740.

    Article  CAS  PubMed  Google Scholar 

  3. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W et al. ULBPs, novel MHC class-I-related molecules, bind to CMV glicoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123–133.

    Article  CAS  PubMed  Google Scholar 

  4. Maeurer MJ, Martin D, Walter W, Liu K, Zitvogel L, Halusczcak K et al. Human intestinal Vdelta1+ lymphocytes recognize tumour cells of epithelial origin. J Exp Med 1996; 183: 1681–1696.

    Article  CAS  PubMed  Google Scholar 

  5. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R et al. Regulation of cutaneous malignancies by gamma-delta T cells. Science 2001; 294: 605–609.

    Article  CAS  PubMed  Google Scholar 

  6. Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR . Human γδ T lymphocytes: a nonredundant system in the immune surveillance against cancer. Trends Immunol 2002; 23: 14–18.

    Article  CAS  PubMed  Google Scholar 

  7. Das H, Groh V, Kuijl C, Sujita M, Morita CT, Spies T et al. MICA engagement by human Vγ2/Vδ2 T cells enhances their antigen-dependent effector functions. Immunity 2001; 15: 83–93.

    Article  CAS  PubMed  Google Scholar 

  8. Sutherland CL, Rabinovich B, Chalupny NJ, Brawand P, Miller R, Cosman D . ULBPs, human ligands of the NKG2D receptor, stimulate tumour immunity with enhancement by IL-15. Blood 2006; 108: 1313–1319.

    Article  CAS  PubMed  Google Scholar 

  9. Catellani S, Poggi A, Bruzzone A, Dadati P, Ravetti J-L, Gobbi M et al. Expansion of Vδ1 T lymphocytes producing IL-4 in low grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood 2007; 109: 2078–2085.

    Article  CAS  PubMed  Google Scholar 

  10. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumour cell lines of different histotypes: analysis of tumour susceptibility to NKG2D-dependent natural killer cell cytoxicity. Cancer Res 2002; 62: 6178–6186.

    CAS  PubMed  Google Scholar 

  11. Nowbakht P, Ionescu M-CS, Rohner A, Kalberer CP, Rossy E, Mori L et al. Ligands for natural killer cell-activating receptors are expressed upon maturation of normal myelomonocytic cells but expressed at low levels in acute myeloid leukemias. Blood 2005; 105: 3615–3622.

    Article  CAS  PubMed  Google Scholar 

  12. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389–1396.

    Article  CAS  PubMed  Google Scholar 

  13. Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK et al. Interaction of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetic 2001; 53: 279–287.

    Article  CAS  Google Scholar 

  14. Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips SJ et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000; 12: 721–727.

    Article  CAS  PubMed  Google Scholar 

  15. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetilase inhibitor sodium valproate. Cancer Res 2005; 65: 6321–6329.

    Article  CAS  PubMed  Google Scholar 

  16. Diermayr S, Himmelreich H, Durovic B, Mathys-Scheeberger A, Siegler U, Langenkamp U et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK cell lines with single KIR HLA-class I specificities. Blood 2008; 111: 1428–1436.

    Article  CAS  PubMed  Google Scholar 

  17. Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A . Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res 2007; 31: 1393–1402.

    Article  CAS  PubMed  Google Scholar 

  18. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M et al. Vδ1T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukaemic B cells and upregulated by transretinoic acid. Cancer Res 2004; 64: 9172–9179.

    Article  CAS  PubMed  Google Scholar 

  19. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.

    Article  CAS  PubMed  Google Scholar 

  20. Fleige S, Walf W, Huch S, Prgomet C, Sehm J, Pfaffl MW . Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett 2006; 28: 1601–1613.

    Article  CAS  PubMed  Google Scholar 

  21. Waldauer I, Steinle A . Proteolytic release of soluble UL-16 binding protein 2 from tumour cells. Cancer Res 2006; 66: 2520–2526.

    Article  Google Scholar 

  22. Alter G, Malenfant JM, Altfeld M . CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294: 15–22.

    Article  CAS  PubMed  Google Scholar 

  23. Sabouri AH, Usuku K, Hayashi D, Izumo S, Ohara Y, Osame M et al. Impaired function of human T lymphotropic virus type 1 (HTLV-1) specific CD8+ T cells in HTLV-1-associated neurological disease. Blood 2008; 112: 2411–24240.

    Article  CAS  PubMed  Google Scholar 

  24. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J et al. MHC class I-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci (USA) 2008; 105: 1285–1290.

    Article  CAS  Google Scholar 

  25. Groh V, Wu J, Yee C, Spies T . Tumour-derived soluble MIC ligands impair expression of NKG2D and T cell activation. Nature 2002; 419: 734–738.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was mainly supported by grants from the Italian Association for Cancer Research (to AP and MRZ), and partially by grants from Compagnia del San Paolo n.2007.2065 to AP and from Final.Min.Sal.2006 (targeting tumor-related immunosuppression for new combined approaches of immunotherapy). We thank Amgen for providing the anti-ULBPs antibodies (M.T.A n.200309766-001).

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to A Poggi or M R Zocchi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poggi, A., Catellani, S., Garuti, A. et al. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 23, 641–648 (2009). https://doi.org/10.1038/leu.2008.354

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.354

Keywords

This article is cited by

Search

Quick links